Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 7903511.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors examined continued neuroleptic exposure following inpatient treatment of mania with neuroleptics and lithium through structured chart review of 40 consecutive patients. At discharge, patients were receiving a mean of 793 mg/day (SD = 695) chlorpromazine equivalents; 6 months later they were receiving a mean of 634 mg/day (SD = 684). This decrease was statistically significant, but the patients' ongoing neuroleptic exposure remained substantial.
Medical subject headings
- Ambulatory Care
- Antipsychotic Agents
- Bipolar Disorder
- Hospitalization
- Lithium